|
此文章由 oldqin 原创或转贴,不代表本站立场和观点,版权归 oursteps.com.au 和作者 oldqin 所有!转贴必须注明作者、出处和本声明,并保持内容完整
给考拉的树 发表于 2016-7-8 16:42 
好的.
他们开始一级实验了没有?一般都是小厂做一二级, 数据好的话融资做三级..
被收购的这个药已经过1期了,明年Q1开始2期
News flow
20
PXS4728A Phase 2 commences &
~A$25M milestone payable (Q1)
Boehringer Ingelheim
SSAO inhibitor PXS4728A sold to Boehringer Ingelheim in May 2015
Excellent partner:
– Boehringer leaders in metabolic disease
– Industry leading development times
– Boehringer responsible for all development, and commercialisation
activities
Competitive deal:
– Total potential payments to approval for 2 indications: €418.5m
(~A$600m),
• Upfront (May 2015): €27.5m (~A$39m)
• Commencement of phase 2 and 3: up to total €55m (~A$80m)
• Filing, regulatory & pricing approvals: up to total €140m(~A$200m)
• second indication: additional total milestone payments (€195m)
– Earn‐out payments on annual net sales
• tiered percentages increasing from high single digits
• plus potential sales milestones |
评分
-
查看全部评分
|